Oncolytic virus carrying shRNA targeting SATB1 inhibits prostate cancer growth and metastasis

Area of Science:

• Oncology
• Virology
• Molecular Biology

Background:

• SATB1 (Special AT-rich sequence-binding protein 1) is identified as a potential therapeutic target for prostate cancer.
• Developing novel agents targeting SATB1 is crucial for advancing prostate cancer treatment.

Purpose of the Study:

• To construct ZD55-SATB1, an oncolytic adenovirus carrying shRNA against SATB1.
• To evaluate the efficacy of ZD55-SATB1 in inhibiting prostate cancer cell growth, viability, invasion, and metastasis.

Main Methods:

• Construction and characterization of ZD55-SATB1.
• In vitro assessment of SATB1 expression inhibition (RT-PCR, Western blot), cytotoxicity (MTT assay), and cell invasion (Matrigel assay) in prostate cancer cell lines (DU145, LNCaP).
• In vivo evaluation of antitumor activity in a prostate cancer xenograft mouse model.

Main Results:

• ZD55-SATB1 demonstrated selective replication and significant reduction of SATB1 expression in prostate cancer cells.
• In vitro studies showed ZD55-SATB1 effectively inhibited cancer cell viability and invasion.
• In vivo experiments confirmed ZD55-SATB1's ability to inhibit tumor growth and metastasis in mice.

Conclusions:

• Replicative oncolytic adenovirus ZD55-SATB1 armed with SATB1 shRNA exhibits significant antitumor effects against human prostate cancer.
• ZD55-SATB1 presents a promising therapeutic strategy for prostate cancer treatment, warranting further clinical development.